Histone H3 acetylation is associated with reduced p21WAFI/CIPI expression by gastric carcinoma

Journal of Pathology

Volumn 205, Issue 1, 2005, Pages 65-73

  Mitani, Yoshitsugu ^a,b   Oue, Naohide ^a   Hamai, Yoichi ^a   Aung, Phyu Phyu ^a   Matsumura, Shunji ^a   Nakayama, Hirofumi ^a   Kamata, Nobuyuki ^b   Yasui, Wataru ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Chromatin immunoprecipitation; Gastric carcinoma; Histone acetylation; Histone H3; Histone H4; P21WAFI CIPI; P53

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; HISTONE H4; MESSENGER RNA; MUTANT PROTEIN; PROTEIN P53; TRICHOSTATIN A;

ACETYLATION; ARTICLE; CANCER CELL CULTURE; CANCER TISSUE; CHROMATIN; CLINICAL ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENETIC CODE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; IN VIVO STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; STOMACH CARCINOMA; WILD TYPE;

ACETYLATION; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA MUTATIONAL ANALYSIS; GENES, P53; HISTONES; HUMANS; MUTATION; NEOPLASM PROTEINS; PROMOTER REGIONS (GENETICS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; STOMACH NEOPLASMS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 11144286644     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1684     Document Type: Article

References (42)

1. Yasui W, Oue N, Ono S, Mitani Y, Ito R, Nakayama H. Histone acetylation and gastrointestinal carcinogenesis. Ann N Y Acad Sci 2003; 983: 220-231.
2. Oue N, Hamai Y, Mitani Y, et al. Gene expression profile of gastric carcinoma: identification of genes and tags potentially involved in invasion, metastasis, and carcinogenesis by serial analysis of gene expression. Cancer Res 2004; 64: 2397-2405.
3. Yasui W, Akama Y, Kuniyasu H, et al. Expression of cyclin-dependent kinase inhibitor p21WAF1/CIP1 in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity. J Pathol 1996; 180: 122-128.
4. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75: 817-825.
5. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-816.
6. Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994; 211: 90-98.
7. Naka K, Yokozaki H, Domen T, et al. Growth inhibition of cultured human gastric cancer cells by 9-cis-retinoic acid with induction of cdk inhibitor Waf1/Cip1/Sdi1/p21 protein. Differentiation 1997; 61: 313-320.
8. Naka K, Yokozaki H, Yasui W, Tahara H, Tahara E. Effect of antisense human telomerase RNA transfection on the growth of human gastric cancer cell lines. Biochem Biophys Res Commun 1999; 255 753-758.
9. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nature Rev Genet 2002; 3: 415-428.
10. Kass SU, Pruss D, Wolffe AP. How does DNA methylation repress transcription? Trends Genet 1997; 13: 444-449.
11. Oue N, Motoshita J, Yokozaki H, et al. Distinct promoter hypermethylation of p16INK4a, CDH1, and RAR-beta in intestinal, diffuse-adherent, and diffuse-scattered type gastric carcinomas. J Pathol 2002; 198: 55-59.
12. Oue N, Oshimo Y, Nakayama H, et al. DNA methylation of multiple genes in gastric carcinoma: association with histological type and CpG island methylator phenotype. Cancer Sci 2003; 94: 901-905.
13. Roman-Gomez J, Castillejo JA, Jimenez A, et al. 5′ CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 2002; 99: 2291-2296.
14. Shin JY, Kim HS, Park J, Park JB, Lee JY. Mechanism for inactivation of the KIP family cyclin-dependent kinase inhibitor genes in gastric cancer cells. Cancer Res 2000; 60: 262-265.
15. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997; 389: 349-352.
16. Eberharter A, Becker PB. Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Rep 2002; 3: 224-229.
17. Urnov FD, Wolffe AP. Chromatin remodeling and transcriptional activation: the cast (in order of appearance). Oncogene 2001; 20 2991-3006.
18. Luger K, Richmond TJ. The histone tails of the nucleosome. Curr Opin Genet Dev 1998; 8: 140-146.
19. Luger K, Mader AW, Richmond RK, Sargent DF, Richmond TJ. Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature 1997; 389: 251-260.
20. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 2000; 97: 10014-10019.
21. Takakura M, Kyo S, Sowa Y, et al. Telomerase activation by histone deacetylase inhibitor in normal cells. Nucleic Acids Res 2001; 29: 3006-3011.
22. Suzuki T, Yokozaki H, Kuniyasu H, et al. Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int J Cancer 2000; 88: 992-997.
23. Kristjuhan A, Walker J, Suka N, et al. Transcriptional inhibition of genes with severe histone h3 hypoacetylation in the coding region. Mol Cell 2002; 10: 925-933.
24. Lauren P. The two histological main types of gastric carcinoma. Diffuse and so-called intestinal type carcinoma: an attempt at histological classification. Acta Pathol Microbiol Scand 1965; 64: 31-49.
25. Sobin LH, Wittekind CH (eds). TNM Classification of Malignant Tumors (5th edn). Wiley-Liss: New York, 1997; 59-62.
26. Ochiai A, Yasui W, Tahara E. Growth-promoting effect of gastrin on human gastric carcinoma cell line TMK-1. Jpn J Cancer Res 1985; 76: 1064-1071.
27. Yanagihara K, Seyama T, Tsumuraya M, Kamada N, Yokoro K. Establishment and characterization of human signet ring cell gastric carcinoma cell lines with amplification of the c-myc oncogene. Cancer Res 1991; 51: 381-386.
28. Ferreira R, Naguibneva I, Mathieu M, et al. Cell cycle-dependent recruitment of HDAC-1 correlates with deacetylation of histone H4 on an Rb-E2F target promoter. EMBO Rep 2001; 2: 794-799.
29. Kondo T, Oue N, Yoshida K, et al. Expression of POT1 is associated with tumor stage and telomere length in gastric carcinoma. Cancer Res 2004; 64: 523-529.
30. Yasui W, Ayhan A, Kitadai Y, et al. Increased expression of p34cdc2 and its kinase activity in human gastric and colonic carcinomas. Int J Cancer 1993; 53: 36-41.
31. Oue N, Shigeishi H, Kuniyasu H, et al. Promoter hypermethylation of MGMT is associated with protein loss in gastric carcinoma. Int J Cancer 2001; 93: 805-809.
32. Avantaggiati ML, Ogryzko V, Gardner K, Giordano A, Levine AS, Kelly K. Recruitment of p300/CBP in p53-dependent signal pathways. Cell 1997; 89: 1175-1184.
33. Espinosa JM, Emerson BM. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol Cell 2001; 8: 57-69.
34. Gartel AL, Tyner AL. Transcriptional regulation of the p21(WAF1/CIP1) gene. Exp Cell Res 1999; 246: 280-289.
35. Lagger G, Doetzlhofer A, Schuettengruber B, et al. The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol Cell Biol 2003; 23: 2669-2679.
36. Sambucetti LC, Fischer DD, Zabludoff S, et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem 1999; 274: 34940-34947.
37. Lagger G, O'Carroll D, Rembold M, et al. Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression. EMBO J 2002; 21: 2672-2681.
38. Wan JS, Mann RK, Grunstein M. Yeast histone H3 and H4 N termini function through different GAL1 regulatory elements to repress and activate transcription. Proc Natl Acad Sci U S A 1995; 92 5664-5668.
39. Sowa Y, Orita T, Hiranabe-Minamikawa S, et al. Histone deacetylase inhibitor activates the p21/WAF1/Cip1 gene promoter through the Sp1 sites. Ann N Y Acad Sci 1999; 886: 195-199.
40. Walia H, Chen HY, Sun JM, Holth LT, Davie Jr. Histone acetylation is required to maintain the unfolded nucleosome structure associated with transcribing DNA. J Biol Chem 1998; 273: 14516-14522.
41. Kelly WK, Richon VM, O'Connor O, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003; 9: 3578-3588.
42. Carducci MA, Gilbert J, Bowling MK, et al. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on a 120-h infusion schedule. Clin Cancer Res 2001; 7: 3047-3055.